Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre - A National Danish Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
We studied whether the severity of GH deficiency (GHD) defined as i) GH-peak on stimulation tests (insulin tolerance test (ITT), arginine, and glucagon), ii) number of additional pituitary deficits, or iii) baseline IGF1 SDS could impact the response to GH treatment. We further explored whether iv) IGF1 SDS after 24 months of GH replacement or v) ΔIGF1 SDS from baseline to 24 months was related to the phenotypic response to GH treatment. DESIGN, PATIENTS, AND MEASUREMENTS: The patient cohort (n=1752; 50% women) was obtained from KIMS (Pfizer International Metabolic Database). The patients were divided into three groups of approximately equal size (tertiles) according to the stimulated GH-peak values and baseline IGF1 SDS and were studied at baseline, 12, and 24 months of GH therapy.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind168
Udgave nummer5
Sider (fra-til)733-43
Antal sider11
ISSN0804-4643
DOI
StatusUdgivet - maj 2013

ID: 39031475